Background: RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed bysunitinib at progression compared with the opposite (standard) sequence in patients with metastatic renal cell carcinoma(mRCC). This final overall survival (OS) analysis evaluated mature data for secondary end points. Patients and methods: Patients received either first-line everolimus followed by second-line sunitinib at progression (n=238)or first-line sunitinib followed by second-line everolimus (n=233). Secondary end points were combined first- and second-lineprogression-free survival (PFS), OS, and safety. The impacts of neutrophil lymphocyte ratio (NLR) and baseline levels of solublebiomarkers on OS were explored. Results: At final analysis, median duration of exposure was 5.6 months for everolimus and 8.3 months for sunitinib. Median combined PFS was 21.7 months [95% confidence interval (CI) 15.1-26.7] with everolimus-sunitinib and 22.2 months(95% CI 16.0-29.8) with sunitinib-everolimus [hazard ratio (HR)EVE-SUN/SUN-EVE, 1.2; 95% CI 0.9-1.6]. Median OS was 22.4 months(95% CI 18.6-33.3) for everolimus-sunitinib and 29.5 months (95% CI 22.8-33.1) for sunitinib-everolimus (HREVE-SUN/SUN-EVE, 1.1;95% CI 0.9-1.4). The rates of grade 3 and 4 adverse events suspected to be related to second-line therapy were 47% with everolimusand 57% with sunitinib. Higher NLR and 12 soluble biomarker levels were identified as prognostic markers for poor OS withthe association being largely independent of treatment sequences. Conclusions: Results of this final OS analysis support the sequence of sunitinib followed by everolimus at progression inpatients with mRCC. The safety profiles of everolimus and sunitinib were consistent with those previously reported, and therewere no unexpected safety signals.
All Science Journal Classification (ASJC) codes